Sanofi GetGoal Programme On Lyxumia(R) (lixisenatide), As An Add-On To Basal Insulin, Shows Significant Positive Phase III Results

Sanofi announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing the…
Diabetes News From Medical News Today

Responses are currently closed, but you can trackback from your own site.

Comments are closed.

Copyright 2010 DiabetesSigns.org, Inc. All rights reserved. The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments. See the Terms of Service for more information. Privacy Policy

Powered by Yahoo! Answers